Beyond Air, Inc. (XAIR) Form 8-K — Jun 26, 2026
Beyond Air reported financial results for the fiscal year ended March 31, 2026, with revenue surging 107% year-over-year to $7.7 million driven by demand for the LungFit PH system. The company reduced its net loss to $33.2 million, or $4.01 per share, from $46.6 million in the prior year, and highlighted a new GPO agreement and expansion into more than 45 countries. The company provided revenue guidance of $8 million for the calendar year 2026 and $16 million to $18 million for 2027, representing more than 110% growth at the midpoint for 2027. Management anticipates a significant inflection point pending FDA approval of its second-generation LungFit PH system, which could expand the U.S.
Key figures
- Revenue
- 7679000
- Guidance
- $8 million for 2026; $16-$18 million for 2027
- Total Debt
- 21600000
- Revenue Yoy
- 107%
- Cash Position
- 17300000
- Q4 Revenue
- 1900000
- TAM US Projected
- $400 million
- TAM WW Projected
- $1 billion
- Q4 Revenue Growth
- 66%
- Reverse Split Ratio
- 1-for-20
Price after filing
Close on the filing date to close N calendar days later (from $0.48). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.